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August 2019 Long-term Efficacy and Safety of Besifovir vs Tenofovir in CHB 1851patients in the BSV–BSV and 85.7% of patients in the TDF–BSV had a virologic response. At
week 48, changes in hip and spine BMD differed signiﬁcantly between the BSV and TDF groups,
whereas the estimated glomerular ﬁltration rate in the TDF group was signiﬁcantly lower than
that in the BSV group. However, at 96 weeks, there were no signiﬁcant differences in BMD and
estimated glomerular ﬁltration rate between the BSV-BSV and TDF-BSV groups.CONCLUSIONS: BSV has antiviral efﬁcacy comparable to that of TDF after 48 weeks of treatment, with durable
effects for 96 weeks. BSV has a better safety proﬁle than TDF, in terms of bone and renal
outcomes. ClinicalTrials.gov no: NCT01937806.Keywords: eGFR; Acyclic Nucleotide Phosphonate; Drug Resistance; Nephrotoxicity.Chronic hepatitis B (CHB) remains a challengingglobal public health burden, causing signiﬁcant
morbidity and mortality despite the availability of
effective antiviral therapies.1–3 The ultimate goals of
anti–hepatitis B virus (HBV) treatment are the eradica-
tion of HBV infection and achieving a functional cure.1,4
Currently, nucleos(t)ide analogues (NAs), which
have high genetic barriers to resistance, regardless of
the severity of hepatic disease, are used as ﬁrst-line
therapies for CHB, and preferred regimens include
entecavir (ETV), tenofovir disoproxil fumarate (TDF),
and tenofovir alafenamide (TAF) monotherapy.1 How-
ever, existing therapies are not sufﬁciently satisfactory
because hepatic decompensation or hepatocellular
carcinoma (HCC) may still develop in some patients
with CHB despite achievement of a complete virologic
response.5–7 In addition, patients on ETV may develop
drug resistance, particularly those exposed to lam-
ivudine.8 Moreover, because TDF can cause nephro-
toxicity and bone mineral density (BMD) loss, patients
at high risk of developing renal and bone-related dis-
eases should be considered for receipt of either ETV or
TAF on the basis of lamivudine treatment history.1,9–12
Therefore, new therapeutic agents are necessary,
including newer NAs or drugs that can act on alterna-
tive steps in viral replication.
Besifovir dipivoxil maleate (BSV), an acyclic nucleo-
tide phosphonate (a guanosine monophosphate), has
been investigated in several phase Ia/IIb studies. In
previous studies, BSV has potent viral suppression of
HBV replication.13–16 The present phase III trial was
designed to compare the antiviral efﬁcacy and safety of
BSV and TDF in CHB patients after a 48-week treatment
period. Moreover, an additional 48-week extension study
was designed to evaluate the long-term efﬁcacy and
safety of BSV treatment in BSV-BSV and TDF-BSV groups
at week 96.Methods
Study Participants
In this nationwide study, 197 patients were pro-
spectively enrolled at 22 representative sites in theRepublic of Korea according to the following criteria.
Eligible patients were aged >20 years and were positive
for hepatitis B surface antigen (HBsAg) for at least 6
months before screening. According to the clinical prac-
tice guidelines released in 2012,17 HBV DNA levels
>1.0  106 copies/mL (17,241 IU/mL) for hepatitis B e
antigen (HBeAg)-positive patients and >1.0  105
copies/mL (1724 IU/mL) for HBeAg-negative patients
were required to initiate antiviral treatment. Study pa-
tients received no antiviral therapy, including pegylated
interferon or oral NAs, for more than 12 weeks before
screening. Patients were also required to have serum
alanine aminotransferase (ALT) levels range from 1.2 to
10 times the upper limit of normal and creatinine
clearance of more than 50 mL/min as calculated by using
the Modiﬁcation of Diet in Renal Disease formula. Writ-
ten informed consent was obtained from all study par-
ticipants. Full eligibility criteria are presented in the
Supplementary Data.Study Design
We conducted a multi-center, randomized, double-
blind, phase III study to evaluate the antiviral efﬁcacy
and safety of BSV versus TDF in CHB patients. The pa-
tients were randomly assigned in a 1:1 ratio by stratiﬁed
block randomization according to whether they were
HBeAg positive or negative at baseline, with a block size
of 2, 4, or 8, to receive either BSV (Ildong Pharmaceutical
Co, Ltd, Seoul, Korea) or TDF (Gilead Sciences, Foster
City, CA) by using a central, interactive, web-based
response system. Patients in the BSV group were
administered 150 mg BSV and TDF placebo with 660 mg
L-carnitine as a supplement, and those in the TDF group
were administered 300 mg TDF and BSV placebo with
L-carnitine placebo to maintain investigator and patient
blinding. After the 48-week treatment period, all patients
enrolled in the extension study received open-label 150
mg BSV and 660 mg L-carnitine for 48 weeks.Endpoints
The efﬁcacy endpoint was the virologic response,
deﬁned as the proportion of patients with HBV DNA
What You Need to Know
Background
Besifovir dipivoxil maleate (BSV) has activity against
hepatitis B virus (HBV). We performed a phase 3
study to compare the antiviral efﬁcacy and safety of
BSV vs tenofovir disoproxil fumarate (TDF) in pa-
tients with chronic HBV infection in Korea.
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ondary efﬁcacy endpoints included the proportion of
patients with HBV DNA <20 IU/mL, which is the limit of
detection, HBsAg or HBeAg seroconversion, normalization
of ALT levels, and emergence of drug resistance during 96
weeks of treatment. Adverse events, BMD, renal parame-
ters, and other laboratory abnormalities were evaluated
for safety analysis. For the details regarding the materials
used, refer to the Supplementary Data.Findings
BSV has antiviral efﬁcacy comparable to that of TDF
after 48 weeks of treatment, with durable effects for
96 weeks. BSV has a better safety proﬁle than TDF in
terms of bone and renal outcomes.
Implications for patient care
BSV is safe and effective for treatment of chronic HBV
infection.Statistical Analysis
A sample size of at least 94 patients per group was
required to demonstrate whether BSV was non-
inferior to TDF in terms of the virologic response
(HBV DNA <69 IU/mL) at week 48, assuming that the
percentage of respondents who reached the virologic
response was 86.2%18 using standard statistical
criteria (80% statistical power, 2.5% one-sided sig-
niﬁcance level, 15% non-inferiority margin, and 10%
dropout).
For primary efﬁcacy analysis, the proportion of pa-
tients with HBV DNA <69 IU/mL was compared with
the test non-inferiority of BSV by using intention-to-
treat analysis. In addition, differences in baseline
characteristics and secondary endpoints between the
treatment groups were tested by using an independent
two-sample t test or Wilcoxon rank sum test for
continuous variables and a c2 test or Fisher exact test
for categorical variables. Individual patient data were
stratiﬁed by HBeAg status at baseline for primary and
secondary efﬁcacy analyses.Results
Study Population
We screened 291 patients with CHB between
November 2013 and February 2016, 194 of whom were
enrolled and randomly assigned to the BSV (n ¼ 98) or
TDF (n ¼ 96) group. A total of 187 patients completed
the 48-week main treatment period. Thirteen patients
did not agree to participate in the extended study for the
additional 48 weeks, and 4 patients were dropped out
from the study because of either HCC occurrence (n ¼ 3)
or creatine phosphokinase elevation (n ¼ 1), leaving a
total of 170 patients who entered into a 96-week
extension study. Nine patients were eliminated from
the study because of consent withdrawal (n ¼ 6),
administration of prohibited medication (n ¼ 2), and
essential thrombocythemia (n ¼ 1). Finally, 161 patients
completed an extension study regardless of virologic
response (Supplementary Figure 1).
Both treatment groups were well-balanced in terms
of age, sex, HBeAg status, serum HBV DNA concentration,
ALT levels, and HBV genotypic distribution (Table 1).Virologic Response
We evaluated the primary outcome by comparing the
suppression of HBV DNA replication (<69 IU/mL) at
week 48 between the 2 treatment groups. There was a
small difference in the proportion of patients who met
the primary endpoint (80.9% [76/94] in the BSV group
and 84.9% [79/93] in the TDF group [lower bound 95%
conﬁdence interval (CI), 14.9%; P ¼ .46; Table 2).
Because the lower bound of 95% CI of the difference in
the virologic response rate was greater than the
predetermined 15% margin, the BSV group met the
efﬁcacy endpoint of non-inferiority to TDF. In subgroup
analysis based on HBeAg status at baseline, among
HBeAg-positive patients, 69.6% in the BSV group and
74.6% in the TDF group met the primary endpoint, and
all HBeAg-negative patients, except 1 BSV group patient,
achieved the virologic response at week 48. The pro-
portion of patients with HBV DNA <20 IU/mL after 48
weeks of treatment was 63.8% in the BSV group and
68.8% in the TDF group, which was not signiﬁcantly
different (P ¼ .47). During the 96-week study period,
87.2% of the BSV-BSV group patients (75/86) and 85.7%
of the TDF-BSV group patients (72/84) had an HBV DNA
level <69 IU/mL at week 96, indicating no signiﬁcant
difference between the 2 groups (P ¼ .78). At week 96,
81.4% of the BSV-BSV group patients and 77.4% in the
TDF-BSV group had HBV DNA level <20 IU/mL; how-
ever, the difference was not statistically signiﬁcant at any
time point throughout the 96 weeks (Figure 1).
Serologic and Biochemical Responses
Among the HBeAg-positive patients, the HBeAg
seroconversion rate was 5.7% in the BSV group and
2.0% in the TDF group, with no signiﬁcant difference
between the 2 groups (P ¼ .62). No BSV group patients
showed an HBsAg loss, and only 1 patient in the TDF
Table 1. Baseline Characteristics of Study Participants
BSV group (n ¼ 94) TDF group (n ¼ 93) Total (n ¼ 187) P value
Sex
Male 60 (63.8) 59 (63.4) 119 (63.6) .96
Age (y)
Median (Q1, Q3) 47 (39, 54) 43 (37, 50) 46 (38, 52) .09
HBV genotype
A 1 (1.1) 0 (0.0) 1 (0.5) 1.00
C 92 (97.9) 92 (98.9) 184 (98.4)
D 0 (0.0) 1 (1.1) 1 (0.5)
Not determined 1 (1.1) 0 (0.0) 1 (0.5)
HBsAg titer (IU/mL)
Median (Q1, Q3) 2929.25 (1951.8, 4019.6) 2925.7 (2008.6, 3573.7) 2925.74 (1987.7, 3826.3) .38
HBeAg
Negative 38 (40.4) 38 (40.9) 76 (40.6) .95
Positive 56 (59.6) 55 (59.1) 111 (59.4)
Serum HBV DNA (log10 IU/mL)
Median (Q1, Q3) 6.2 (5.0, 8.2) 6.76 (5.57, 8.1) 6.55 (5.32, 8.1) .39
Serum ALT (U/L)
Median (Q1, Q3) 76.5 (53.0, 118.0) 80 (55, 150) 78 (53, 140) .30
eGFR by MDRD (mL/min)
Median (Q1, Q3) 88.8 (77.6, 100.4) 90.8 (80.3, 102.3) 89.7 (78.5, 101.5) .25
Creatinine (mg/dL)
Median (Q1, Q3) 0.8 (0.7, 1.0) 0.8 (0.8, 0.9) 0.8 (0.7, 1.0) .52
Phosphate (mg/dL)
Median (Q1, Q3) 3.6 (3.2, 3.8) 3.5 (3.0, 3.9) 3.50 (3.1, 3.9) .23
Hip BMD
Normal (T-score  1.0) 65 (83.3) 52 (82.5) 117 (83) .90
Osteopenia (2.5 < T-score < 1.0) 13 (16.7) 11 (17.5) 24 (17.0)
Osteoporosis (T-score  2.5) 0 (0.0) 0 (0.0) 0 (0.0)
Spine BMD
Normal (T-score  1.0) 56 (65.9) 53 (68.8) 109 (67.3) .85
Osteopenia (2.5 < T-score < 1.0) 24 (28.2) 21 (27.3) 45 (27.8)
Osteoporosis (T-score  2.5) 5 (5.9) 3 (3.9) 8 (4.9)
Cardiovascular disease 0 (0.0) 0 (0.0) 0 (0.0) —
Diabetes mellitus types 1 and 2 12 (12.8) 4 (4.3) 16 (8.6) .04
Hypertension 11 (11.7) 10 (10.8) 21 (11.2) .84
Dyslipidemia 2 (2.1) 2 (2.2) 4 (2.1) 1.00
Cirrhosis 24 (25.5) 17 (18.3) 41 (21.9) .23
Prior antiviral therapy 0 (0.0) 1a (1.1) 1a (0.5) 1.00
NOTE. Data are expressed as n (%), unless stated otherwise.
ALT, alanine aminotransferase; BMD, bone mineral density; BSV, besifovir dipivoxil maleate; eGFR, estimated glomerular ﬁltration rate; MDRD, Modiﬁcation of Diet
in Renal Disease; TDF, tenofovir disoproxil fumarate.
aViread (tenofovir disoproxil fumarate).
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treatment. Subgroup analysis showed no signiﬁcant dif-
ference in the HBeAg seroconversion rate between the
BSV-BSV and TDF-BSV groups after 96 weeks of treat-
ment. No HBsAg loss was observed after the 96-week
treatment in the BSV-BSV group, and only 1.3% of
TDF-BSV group patients (1/77) showed an HBsAg loss
(Table 2).
The proportions of patients whose ALT levels
normalized after 48 weeks of treatment were 73.4% in
the BSV group and 74.2% in the TDF group, with no
signiﬁcant difference between the groups (P ¼ .90)
(Table 2). Nevertheless, after 96 weeks, there was a
signiﬁcant difference in the proportions of patients with
ALT normalization (P ¼ .01), 73.3% in the BSV-BSV
group (63/86) and 88.1% in the TDF-BSV group(74/84). However, the proportions of patients with HBV
DNA <69 IU/mL and ALT normalization were not
signiﬁcantly different between the 2 groups (65.1%
versus 77.4%, respectively; P ¼ .08).Virologic Breakthrough
None of the patients whose HBV DNA was sequenced
during 48 weeks after the initial administration of BSV or
TDF showed any sequence changes. There was no sig-
niﬁcant difference (P ¼ 1.00) in the proportions of pa-
tients showing a virologic breakthrough, 5.3% in the BSV
group and 5.4% in the TDF group. All patients showing a
virologic breakthrough exhibited a transient elevation in
HBV DNA levels, which was subsequently reversed, on
Table 2. Virologic, Serologic, and Biochemical Responses
48 weeks 96 weeks
BSV
(n ¼ 94)
TDF
(n ¼ 93)
Difference
(95% CI) P value
BSV-BSV
(n ¼ 86)
TDF-BSV
(n ¼ 84)
Difference
(95% CI) P value
HBV DNA <69 IU/mL 76 (80.9) 79 (84.9) 4.1 (14.9 to 6.7) .46 75 (87.2) 72 (85.7) 1.5 (8.8 to 11.8) .78
HBV DNA <20 IU/mL 60 (63.8) 64 (68.8) 5.0 (18.5 to 8.5) .47 70 (81.4) 65 (77.4) 4.0 (8.1 to 16.2) .52
HBeAg loss, n/N (%)a 5/53 (9.4) 3/50 (6.0) 3.4 (6.8 to 13.7) .72 11/52 (21.2) 9/44 (20.5) 0.7 (15.6 to 7.0) .93
HBeAg seroconversion,
n/N (%)a
3/53 (5.7) 1/50 (2.0) 3.7 (3.7 to 11.0) .62 6/52 (11.5) 2/44 (4.5) 7.0 (3.7 to 17.6) .28
HBsAg loss, n/N (%)b 0/87 (0) 1/87 (1.1) 1.1 (3.4 to 1.1) 1.00 0/83 (0) 1/77 (1.3) 1.3 (3.8 to 1.2) .48
HBsAg seroconversion,
n/N (%)b
0/87 (0) 0/87 (0) — — 0/83 (0) 0/77 (0) — —
ALT normalization, n (%)c 69 (73.4) 69 (74.2) 0.8 (13.4 to 1.8) .90 63 (73.3) 74 (88.1) 14.8 (26.5 to 3.2) .01
NOTE. Data are expressed as n (%), unless stated otherwise.
ALT, alanine aminotransferase; BSV, besifovir dipivoxil maleate; TDF, tenofovir disoproxil fumarate.
aAmong HBeAg-seropositive and anti–HBe-negative patients at baseline.
bAmong HBsAg-seropositive and anti–HBs-negative patients at baseline.
cAmong patients with baseline ALT levels above the central lab normal range (0–41 U/L for men and 0–33 U/L for women).
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without any additional intervention. During the 96-week
study period, 4.65% of BSV-BSV group patients (4/86)
and 15.48% of TDF-BSV group patients (13/84)Figure 1. Comparison of viral suppression between the BSV-
BSV and TDF-BSV groups. (A) Proportion of patients with
HBV DNA <69 IU/mL by study week. (B) Proportion of pa-
tients with HBV DNA <20 IU/mL by study week. Bars
represent 95% conﬁdence intervals. BSV, besifovir dipivoxil
maleate; HBV, hepatitis B virus; TDF, tenofovir disoproxil
fumarate.experienced a virologic breakthrough (P ¼ .02); how-
ever, all these patients recovered spontaneously without
additional intervention. No antiviral resistance was
detected in the virologic breakthrough.
Safety
There was no signiﬁcant difference in the rates of
overall adverse events between the 2 groups throughout
the study period (Table 3). Consistently, between weeks
48 and 96, there was no signiﬁcant difference in the
adverse events that were newly reported in 61 BSV-BSV
group patients (53.5%) and 57 TDF-BSV group patients
(50.0%). Adverse events with an incidence 5% included
nasopharyngitis, dyspepsia, nausea, back pain, headache,
dizziness, fatigue, and ALT elevation in the BSV-BSV group
and nasopharyngitis, dyspepsia, gastritis, diarrhea, pruri-
tus, and urticaria in the TDF-BSV group. Whereas no
dyspepsia was reported in the BSV group, 8 dyspepsia
events occurred in 7 patients in the TDF group (8.33%)
during the ﬁrst 48-week treatment period. Although there
was no serious adverse event that caused death during
the study period, 1 BSV group patient with HCC and 2 TDF
group patients with either HCC or creatine phosphokinase
elevation discontinued study drug treatment during the
ﬁrst 48-week treatment period. In addition, 1 BSV-BSV
group patient developed tuberculous colitis, and an
additional TDF-BSV group patient developed essential
thrombocythemia, both of whom discontinued treatment
with the study drugs during the extended period.
There were no signiﬁcant changes in the proportion
of BSV-BSV group patients with impaired BMD at week
96 relative to that at baseline. In the TDF group, how-
ever, the proportion of patients with osteopenia and
osteoporosis increased, whereas that of patients with a
normal BMD decreased at week 48 relative to baseline
levels (Supplementary Figure 2). Furthermore, the mean
change in hip BMD from baseline to week 48 was 0.33%
Table 3. Safety Data
Variables
0–48 weeks 48–96 weeks
TotalBSV (n ¼ 86) TDF (n ¼ 84) BSV-BSV (n ¼ 86) TDF-BSV (n ¼ 84)
Adverse events 52 (60.5) 45 (53.6) 46 (53.5) 42 (50.0) 118 (69.4)
Adverse events leading to study drug
discontinuation
0 0 1 (1.2) 1 (1.2) 2 (1.2)
Adverse drug reactions 19 (22.1) 21 (25.0) 14 (16.3) 10 (11.9) 51 (30.0)
Death 0 0 0 0 0
Adverse events recorded in 3% of
all patients
Nasopharyngitis 9 (10.5) 4 (4.8) 6 (7.0) 8 (9.5) 23 (13.5)
Dyspepsia 8 (9.30) 9 (10.7) 0 0 17 (10.0)
Headache 4 (4.7) 3 (3.6) 2 (2.3) 2 (2.4) 9 (5.3)
Back pain 4 (4.7) 0 2 (2.3) 3 (3.6) 9 (5.3)
Fatigue 4 (4.7) 3 (3.6) 1 (1.2) 1 (1.2) 9 (5.3)
Pruritus 2 (2.3) 2 (2.4) 1 (1.2) 3 (3.6) 8 (4.7)
Gastritis 0 2 (2.4) 2 (2.3) 4 (4.8) 8 (4.7)
Nausea 4 (4.7) 1 (1.2) 2 (2.3) 0 7 (4.1)
Alanine aminotransferase elevation 4 (4.7) 2 (2.4) 1 (1.2) 0 7 (4.1)
Diarrhea 0 3 (3.6) 2 (2.3) 2 (2.4) 7 (4.1)
Urticaria 1 (1.2) 1 (1.2) 0 4 (4.8) 6 (3.5)
Dizziness 2 (2.3) 0 4 (4.7) 0 6 (3.5)
Grade 3–4 laboratory abnormalities found
in 1% of all patients
Alanine aminotransferase >5  ULN 9 (10.5) 9 (10.7) 0 (0.0) 0 (0.0) 18 (10.6)
Aspartate aminotransferase >5  ULN 5 (5.8) 4 (4.8) 0 (0.0) 0 (0.0) 9 (5.3)
Platelets <50,000/mm3 2 (2.3) 3 (3.6) 0 (0.0) 0 (0.0) 5 (2.9)
Absolute neutrophil counts <1000/mm3 2 (2.3) 0 (0.0) 1 (1.2) 1 (1.2) 4 (2.4)
Phosphate <0.6 mmol/L 2 (2.3) 2 (2.4) 1 (1.2) 0 (0.0) 4 (2.4)
Proteinuria 1 (1.2) 1 (1.2) 0 (0.0) 1 (1.2) 3 (1.8)
Hematuria 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.4) 2 (1.2)
Creatine phosphokinase >5  ULN 1 (1.2) 1 (1.2) 0 (0.0) 0 (0.0) 2 (1.2)
NOTE. Data are expressed as n (%), unless stated otherwise.
BSV, besifovir dipivoxil maleate; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal.
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which was signiﬁcantly less than the reduction of 0.85%
(95% CI, 2.74% to 1.04%) in patients receiving TDF
(P ¼ .01) (Figure 2A). Similarly, the mean decrease in
spine BMD from baseline to week 48 was 0.04% (95%
CI, 1.64% to 1.57%) in patients receiving BSV, which
was signiﬁcantly less than the reduction of 1.29% (95%
CI, 2.46% to 0.11%) in patients receiving TDF (P <
.05) (Figure 2B). After switching to BSV in the TDF-BSV
group, BMD returned to the baseline level at week 96,
and changes in the T-score at week 96 were not statis-
tically different between the BSV-BSV and TDF-BSV
groups.
The nephrotoxicity-related safety results showed no
signiﬁcant change in serum creatinine in the BSV-BSV
group at week 96 compared with that at baseline. In
contrast, the TDF group showed a signiﬁcant increase in
serum creatinine compared with that in the BSV group at
week 48 (P ¼ .04); however, after switching to BSV, the
difference at week 96 was not statistically signiﬁcant
(P ¼ .42). Moreover, the median changes in estimated
glomerular ﬁltration rate (eGFR) from baseline
were 0.5 mL/min and 0.7 mL/min at weeks 48 and
96, respectively, in the BSV-BSV group, indicating noeffect of BSV on renal function. In the TDF group, the
median change in eGFR from baseline was 7.8 mL/min
at week 48, indicating a decline in renal function. At
week 96, however, the median change was 0.4 mL/min
after switching to BSV, demonstrating a recovery in renal
function (Figure 3).Discussion
This randomized comparative study of BSV versus
TDF for the treatment of CHB demonstrated non-
inferiority of BSV to TDF in the efﬁcacy of viral sup-
pression at week 48, whereas BSV showed a better safety
proﬁle than did TDF in terms of renal and bone param-
eters. Moreover, there were no signiﬁcant differences in
the virologic response rates between the 2 groups,
regardless of HBeAg status. A subsequent extension
study showed that the antiviral effect of BSV was main-
tained up to 96 weeks without serious safety concerns.
Considering the reported virologic response rates of 87%
in HBeAg-negative patients (313/359)19 and 71% in
HBeAg-positive patients (181/254) after 144 weeks of
TDF treatment, BSV treatment showed comparable
Figure 2. Comparison of
changes in BMD between
the BSV-BSV and TDF-
BSV groups. (A) Mean
percentage changes in hip
BMD at weeks 48 and 96
of treatment. Bars repre-
sent 95% conﬁdence in-
terval. (B) Mean
percentage changes in
spine BMD at weeks 48
and 96 of treatment. Bars
represent 95% conﬁdence
intervals. BMD, bone min-
eral density; BSV, besifovir
dipivoxil maleate; TDF,
tenofovir disoproxil
fumarate.
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the antiviral effect of BSV was maintained throughout the
96-week treatment.
According to recent clinical practice guidelines for
CHB, various NAs show a wide range of virologic
response rates at week 48, varying from 13% to 76% for
HBeAg-positive patients to 60% to 93% for HBeAg-
negative patients.1,20 In the current study, the pro-
portions of patients with undetectable HBV DNA (<20
IU/mL) at week 48 were 46.4%–58.2% among HBeAg-
positive patients and 84.2%–89.5% among HBeAg-
negative patients, and these gradually increased during
the 96 weeks of treatment. Nevertheless, HBeAg loss
rates and HBeAg seroconversion rates in the current
study were lower than those in the previous studies.18,21
Most of the patients in this study were infected with
HBV genotype C, which was reported to have a lowerseroconversion rate of HBeAg compared with other HBV
genotypes.22,23
The proportion of patients who achieved the primary
efﬁcacy endpoint of HBV DNA <69 IU/mL after
completing 48 weeks of TDF treatment was 84.9% (79/
93), and that of patients who achieved the virologic
response after an additional 48 weeks of BSV treatment
was 85.7% (72/84) at week 96, suggesting that the
antiviral effect achieved during the ﬁrst 48 weeks of TDF
treatment was not affected by the subsequent 48-week
BSV treatment.
The biochemical response rate at week 96 in the TDF-
BSV group was signiﬁcantly higher than that observed in
the BSV-BSV group. To determine the cause of this dif-
ference, baseline characteristics (presence of cirrhosis
and ALT category) and ALT levels after 48 weeks of
treatment were examined, but no contributing factors
Figure 3. Changes in esti-
mated glomerular ﬁltration
rate from baseline by
study week. Data are pre-
sented as median (Q1, Q3)
values (mL/min) calculated
by using the Modiﬁcation
of Diet in Renal Disease.
BSV, besifovir dipivoxil
maleate; TDF, tenofovir
disoproxil fumarate.
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difference in the proportion of patients with concurrent
virologic (HBV DNA <69 IU/mL) and biochemical (ALT
normalization) responses at weeks 48 and 96 between
the 2 groups (P ¼ .08). Moreover, there was seemingly
no clinically signiﬁcant effect of the medication switch on
biochemical response rates between the 2 groups (P ¼
.28) by using the American Association for the Study of
Liver Diseases criteria20 for normal ranges of ALT (data
not shown).
Our safety analysis of 96 weeks of BSV administration
showed that adverse events occurring with an incidence
5% were similar to those reported for 96-week TDF
treatment.24 Adverse events that occurred during the 48-
week BSV treatment period after 48 weeks of TDF
treatment were similar to those occurring during the 96-
week BSV-BSV treatment period.
Regarding the mean changes in BMD, the TDF group
showed a statistically signiﬁcant decline in BMD at 48
weeks, compared with the BSV group, but this returned
to the baseline BMD level at 96 weeks after switching to
BSV. Moreover, although serial assessments of BMD in
the BSV-BSV group suggested no evidence of bone loss
during 96 weeks of evaluation, we observed a clear
worsening of BMD in terms of the proportion of subjects
with osteopenia or osteoporosis after TDF treatment.
These ﬁndings were predictable on the basis of a study
showing that among TDF-treated subjects, 8.2% devel-
oped osteoporosis and 31.6% had osteopenia at week
96.25 There have also been reports of serious bone
loss–related adverse events or adverse events leading to
TDF discontinuation because of impaired BMD after 7
years of follow-up.26 Because BMD mostly declines dur-
ing 24–48 weeks and up to 144 weeks of TDF treatment,
BSV may be safer than TDF for long-term use in terms ofbone loss issues, particularly in elderly CHB patients
with osteopenia or osteoporosis.
Throughout the 96 weeks of treatment in the present
study, there were no patients who experienced adverse
renal events such as acute renal failure and proximal
tubulopathy, whereas Fanconi syndrome and other renal
insufﬁciencies that have been linked to long-term use of
NAs1,27 were rarely experienced. On the basis of serum
creatinine concentrations and eGFR changes over time,
the BSV-BSV group had a more favorable safety proﬁle
between weeks 24 and 60 than did the TDF-BSV group
(P ¼ .02 and P ¼ .29, respectively). In the TDF-BSV group,
the distribution of eGFR over time is left-tailed, and the
number of individuals with severe eGFR decline increases
with time. At week 36, eGFR decreases by 5.67, and the
time-dependent changes in eGFR by TDF in the pivotal
study began to decrease by an absolute value of 5 or
higher at 36 weeks.24 Moreover, in the TAF registration
clinical trial,21 the TDF group showed a slight decrease
from 8 weeks, but the decrease was not signiﬁcant, so we
do not see much difference in the changing patterns of
eGFR between our results and previous reports on TDF.
Osteoporosis and renal dysfunction are common
complications in patients with cirrhosis.28,29 Although
the BSV group was more likely to have cirrhosis,
cirrhosis did not signiﬁcantly affect BMD and eGFR levels
in multivariate logistic regression analysis. However,
additional multivariate analyses of renal outcomes,
adjusted for age, eGFR, serum creatinine, and cirrhosis at
baseline, were performed and showed more pronounced
differences in renal safety between the groups at week
48 (P ¼ .002 for creatinine; P < .005 for eGFR)
(Supplementary Table 1).
The previous in vivo studies showed that the renal
uptake of BSV was one-fourth of TDF and that the hepatic
1858 Ahn et al Clinical Gastroenterology and Hepatology Vol. 17, No. 9uptake of BSV was twice as high as that of TDF. In
addition, according to the non-clinical distribution test of
LB80317, an active metabolite of BSV administration, it
was found to have the lower systemic exposure and
highest tissue to plasma concentration in the liver (in-
ternal report of LG Chem, Ltd, Korea; data not shown).
Such pharmacologic mechanism of BSV seems to be
beneﬁcial to renal function.
There are some limitations to the present study. First,
the sample size was relatively small, and study population
was only Asian, predominantly with HBV genotype C.
Therefore, larger-scale clinical trials including various
races and HBV genotypes are further required to conﬁrm
the efﬁcacy and safety of BSV in the future. Second,
although overall safety issues associated with nephro-
toxicity were nearly negligible in the BSV-BSV group, renal
function should be regularly monitored every 6–12
months in patients treated with NAs through long-term
follow-up.29 Despite short-term signiﬁcant differences in
bone and renal outcomes between the groups, it is unclear
whether such small differences are clinically relevant
because long-term clinical safety may be similar for BSV
and TDF. Third, the effects of BSV on renal function,
including serum creatinine levels and creatinine clearance
over time, remain to be investigated, particularly in pa-
tients with decompensated cirrhosis or severe renal al-
terations, who would probably need an adjustment to the
BSV dose. In addition, there were no assessments of bone
turnover markers to evaluate bone formation or resorp-
tion or renal tubulopathy markers to quantify albuminuria
such as urinary protein/creatinine ratio and urinary
retinol-binding protein/creatinine ratio or b2-
microglobulin/creatinine ratio. Therefore, a prolonged
clinical study is needed to determine whether BSV is safer
than TDF with regard to nephrotoxicity and BMD.
Nevertheless, it was evident that the antiviral effect
of 96-week BSV treatment is similar to that of current
therapies with a high resistance barrier and that the
safety proﬁle of BSV treatment is more favorable for
CHB patients. BSV was approved by the Korean Min-
istry of Food and Drug Safety in May 2017 and is un-
dergoing a phase III clinical trial for hepatitis B
patients with resistance to NAs. To secure a niche for
its clinical utility, efﬁcacy and safety outcomes from a
long-term follow-up study need to be established, and
additional studies in other special populations
requiring oral antiviral treatments, such as patients
with decompensated cirrhosis, HCC, and serious renal
dysfunction, will be warranted.
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Enrollment Criteria
Inclusion criteria
1. Male or female aged  20 years
2. Subjects who had been HBsAg positive for >6
months before screening or those with history of
CHB
3. Subjects who had not received interferon therapy
(including pegylated interferon) for CHB and who
had not received antiviral therapy for 12 weeks
4. HBsAg-positive subjects during the screening
process
5. Subjects with 1  105 copies/mL (17,241 IU/mL)
of HBV DNA using the COBAS TaqMan HBV test if
HBeAg was positive during screening, or subjects
with 1  104 copies/mL (1724 IU/mL) of HBV
DNA using COBAS TaqMan HBV test if HBeAg was
negative
6. ALT level 1.2  and 10  the upper limit of
normal (ULN)
7. Subjects who were informed of the study purpose,
methods, and outcomes and who had signed a
written consent form.
8. Male and female subjects of childbearing age who
agreed to use a medically approved contraception
method during the study period. (Medically
approved contraception is deﬁned as a condom,
diaphragm, surgical sterilization, intrauterine
contraceptive device, oral contraception, other
hormone delivery system, contraceptive cream,
jelly, or foam.)
Exclusion criteria
1. Hepatitis C virus, hepatitis D virus, or human im-
munodeﬁciency virus infection
2. Subjects with decompensated hepatic disease with
any one of the following indications:- Total bilirubin >2  ULN
- Prothrombin time at least 3 seconds longer than
the normal limit
- Serum albumin <30 g/L
- History of ascites, jaundice, variceal bleeding, or
signs of hepatic encephalopathy3. At least one of the following results at screening:- Hemoglobin <9.0 g/dL
- Absolute neutrophil count <1.5  109/L
- Platelet count <100  109/L- Serum creatinine >1.5 mg/dL
- Serum amylase >2  ULN and serum lipase >2 
ULN4. GFR < 50 mL/min at screening by calculating
Modiﬁcation of Diet in Renal Disease (1.86 
creatinine  1.154  age  0.203 ( 0.742, if
female))
5. Alpha-fetoprotein above 50 ng/mL and suspicion of
HCC on liver computed tomography screening
6. Subjects who had received any of the drugs listed
below within 2 months before screening (except
when the treatment was acute [<14 consecutive
days] or was low-dose aspirin [100–300 mg/day])- Nephrotoxic drugs (eg, aminoglycosides, ampho-
tericin B, and nonsteroidal anti-inﬂammatory
drugs)
- Hepatotoxic drugs (eg, erythromycin, ketocona-
zole, rifampin, ﬂuconazole, and dapsone)
- Anticoagulants (warfarin)7. Subjects who had received immunosuppressive
therapy within 6 months before screening and were
suspected to be immunosuppressed at the discretion
of the investigator
8. Subjects who had received chronic high-dose sys-
temic corticosteroid therapy (20 mg daily
prednisone-equivalent) within 3 months before
screening (in the case of local administration of
corticosteroids, the decision was made at the
discretion of the investigator) (cortisone 125 mg,
hydrocortisone 100 mg, prednisone 20 mg, methyl-
prednisolone 16 mg, triamcinolone 16 mg, dexa-
methasone 3 mg, and betamethasone 2.4 mg)
9. Subjects diagnosed with or having had recurrent
malignant tumor within 5 years before screening (at
the discretion of the investigator, who decided
whether the trial would be affected in the case of a
benign tumor)
10. Planned participation in another clinical study af-
ter entry into this study or having participated in
another clinical study within 3 months of study
entry
11. Women who were pregnant, lactating, or planning a
pregnancy during the study period
12. Hypersensitivity to test drugs
13. History of alcohol or drug abuse within 1 year before
screening or currently have such conditions
14. In addition to hepatic disease, subjects with heart
failure, renal failure, or pancreatitis that might
interfere with the subject’s participation in the
study, at the discretion of the investigator
August 2019 Long-term Efficacy and Safety of Besifovir vs Tenofovir in CHB 1859.e215. Subjects with other hepatic diseases (eg, hemo-
chromatosis, Wilson’s disease, alcoholic hepatitis,
nonalcoholic steatohepatitis, and alpha-1 antitrypsin
deﬁciency)
16. History of organ transplantation
17. Psychiatric or cognitive disorder that might affect
the subject’s ability to perform daily activities or
comprehend the speciﬁed study purpose or
procedures
18. Any condition or situation that might interfere with
the subject’s participation in the study, at the
discretion of the investigator
Methods
Patients were requested to visit at baseline, weeks 4
and 12, and at 12-week intervals thereafter for efﬁcacy
and safety assessments. At each visit, a physical exami-
nation and laboratory tests were conducted in a central
laboratory (GreenCross Lab Cell Corporation, Yongin,
Korea), and BMD assessments were performed. The
study was approved by the institutional review board at
each site. Furthermore, during the main treatment
period, an independent Data Safety Monitoring Board
reviewed the study data with a focus on safety, according
to the Data Safety Monitoring Board management plan.
The clinical trial was conducted in accordance with the
International Conference on Harmonization Guidelines
for Good Clinical Practice and the Declaration of Helsinki.
Laboratory tests included HBV DNA quantiﬁcation by
using a COBAS AmpliPrep/TaqMan test (Roche Di-
agnostics, Indianapolis, IN), with a lower detection limit
of 20 IU/mL, as well as serologic tests such as HBsAg andHBeAg. HBV DNA sequencing by using a BigDye Termi-
nator v3.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA) was performed for patients whose HBV
DNA titer was greater than 1724 IU/mL at 48 weeks or
at any time to verify the presence of resistance mutations
after a virologic breakthrough. A liver biopsy was per-
formed only in patients who agreed to liver biopsy at
baseline and at 48 weeks. BMD measurements of the
lumbar spine and hip were performed by using a dual-
energy x-ray absorptiometry scan at baseline and at 48
and 96 weeks. Glomerular ﬁltration rate was estimated
by using the Modiﬁcation of Diet in Renal Disease.Statistical Analysis
A sample size of at least 94 patients per group was
required to demonstrate whether BSV was non-inferior
to TDF in terms of the virologic response (HBV DNA
<69 IU/mL) at week 48, assuming that the percentage of
respondents who reached the overall virologic response
was 86.2%2 using standard statistical criteria (80%
statistical power, 2.5% one-sided signiﬁcance level, 15%
non-inferiority margin,18 and 10% dropout).
For primary efﬁcacy analysis, the proportion of
patients with HBV DNA <69 IU/mL was compared
with the test non-inferiority of BSV by using intention-
to-treat analysis. In addition, differences in baseline
characteristics and secondary endpoints between the
treatment groups were tested by using independent
two-sample t test or Wilcoxon rank sum test for
continuous variables and c2 test or Fisher exact test
for categorical variables. Individual patient data were
stratiﬁed by HBeAg status at baseline for primary and
secondary efﬁcacy analyses.
Supplementary Figure 1. Patient disposition. BSV, besifovir dipivoxil maleate; CPK, creatine phosphokinase; HCC, hepa-
tocellular carcinoma; TDF, tenofovir disoproxil fumarate.
Supplementary Figure 2. Safety results of bone mineral density in terms of T-score changes from baseline. BSV, besifovir
dipivoxil maleate; TDF, tenofovir disoproxil fumarate.
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Supplementary Table 1. Renal Safety Data at Week 48
BSV (n ¼ 92) TDF (n ¼ 92) Difference (95% conﬁdence interval) P value
Creatinine
LS mean  standard error 0.01  0.01 0.06  0.01 0.05 (0.08 to 0.02) .0024
Median 0.00 0.10
Minimum, maximum 0.40, 0.20 0.10, 0.30
P value .24 <.0001
eGFR
LS mean  standard error 1.87  1.18 6.66  1.18 4.79 (1.48–8.09) .0048
Median 0.45 7.70
Minimum, maximum 30.50, 48.30 33.90, 17.00
P value .11 <.0001
NOTE. Multivariable analysis was adjusted for baseline age, eGFR, serum creatinine, and cirrhosis.
BSV, besifovir dipivoxil maleate; eGFR, estimated glomerular ﬁltration rate; LS, least squares; TDF, tenofovir disoproxil fumarate.
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